Regulators are warning about the use of non-vitamin K antagonist oral anticoagulants in patients with antiphospholipid syndrome.

Product information is being updated to include new data about an increased risk of thrombotic events in patients diagnosed with the syndrome, the TGA says in a safety alert.

The non-vitamin K antagonist oral anticoagulants (NOACs) marketed in Australia are apixaban (Eliquis), dabigatran etexilate (Pradaxa) and rivaroxaban (Xarelto).

The warning comes after a trial showed an increase in the risk of recurrent thrombotic events with rivaroxaban compared with warfarin in patients with antiphospholipid syndrome (APS), a history of thrombosis and a high risk of recurrent thrombotic events.